Incyte's pipeline is making progress as its KRAS G12D inhibitor, INCB161734, in first-line metastatic pancreatic cancer with chemotherapy achieved a confirmed objective response rate of 81%, while 90% of patients remained progression-free at six months.
Incyte's Jakafi is the first FDA-approved treatment for a rare blood disorder known as myelofibrosis, giving it strong pricing power and market penetration.
Several competing myelofibrosis therapies are entering the market and could upend Incyte's monopoly on the myelofibrosis market.
Metric | INCY | ABBV | RHHBY |
|---|---|---|---|
Price/Earnings (Normalized) | 48.66 | 33.44 | 20.84 |
Price/Book Value | 4.37 | — | 9.50 |
Price/Sales | 4.18 | 7.92 | 4.90 |
Price/Cash Flow | 22.54 | 22.25 | 15.33 |
Metric | INCY | ABBV | RHHBY |
|---|---|---|---|
Quick Ratio | 3.54 | 0.56 | 0.80 |
Current Ratio | 3.84 | 0.87 | 1.23 |
Interest Coverage | 283.92 | 5.20 | 13.49 |
Metric | INCY | ABBV | RHHBY |
|---|---|---|---|
Return on Assets (Normalized) | 9.15% | 16.61% | 15.81% |
Return on Equity (Normalized) | 11.94% | — | 48.77% |
Return on Invested Capital (Normalized) | 10.07% | 36.97% | 23.90% |
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|WDtJ$f | LOCK|xpJyg | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|>&W^?@ | LOCK|%qW< | $99B | |||
| Moderna Inc MRNA | LOCK|@$?sH@ | LOCK|b@ | $90B | |||
| argenx SE ADR ARGX | LOCK|MtpJclk | LOCK|@^ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|k?<^d^ | LOCK|<lJ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&kMGZ&C | LOCK|MvHx? | $31B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|jzPBKg | LOCK|#KD>$ | $22B | |||
| BioNTech SE ADR BNTX | LOCK|PM?j#c | LOCK|<<& | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|vJ&#MtS | LOCK|^%w | $16B |
United States